- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Bit Bio Ltd. (Bit.bio)
BioCentury | Dec 5, 2024
Product Development
Stem cell therapy companies take different roads to reproducibility
But they agree that creating a reliable product is necessary for scalability
BioCentury | Sep 19, 2024
Emerging Company Profile
GCTx: Simplifying iPSC-based cell therapy production
Launching with $75M, Cambridge, Mass. start-up aims to shortcut the cell therapy manufacturing process by directly activating transcription factors involved in cell fate
BioCentury | Jul 31, 2024
Management Tracks
Min Liu succeeds Yiping Li as CEO of JW
Plus: John Chin to retire as CBO from Antengene, and updates from ADARx, bit bio and Santhera
BioCentury | Aug 31, 2023
Finance
Aug. 31 Quick Takes: Sage downsizes, reveals executive departures
Plus: CCM launches with $25M+ and updates from Kangpu, Clock Bio, MC2, Huadong and RabPharma
BioCentury | Jun 13, 2023
Management Tracks
Patni becomes chief of R&D at Reata
Plus: Reilly named CEO at Damona, and updates from Akebia, Generate, Jasper and more
BioCentury | Nov 18, 2021
Management Tracks
D’Amelio to retire as Pfizer’s CFO
Plus: BioAge, bit bio, Volastra, Provention and more
BioCentury | Oct 30, 2020
Finance
Oct. 29 Quick Takes: Ultragenyx, Scholar Rock, Galecto, Citrine-Bioprojet, miRagen-Viridian, Elpis, CASI-BioInvent
Ultragenyx, Scholar Rock offerings Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) and Scholar Rock Holding Corp. (NASDAQ:SRRK) raised follow-ons late Wednesday. Ultragenyx raised $400
BioCentury | Jun 16, 2020
Product Development
Bit Bio scales up cell programming ambitions with $41.5M from blue-chip investors
BioCentury | May 25, 2017
Emerging Company Profile
Total reprogramming
Elpis turns stem cells into high-purity cell types for use in disease models
Items per page:
1 - 10 of 10